Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs is a contract research organization (CRO) formed and managed by a team of scientists and specialists with considerable expertise and experience in cell therapy research and development. We are committed to offering superior products and services to clients in the academic and industrial sectors across the world, supporting the pursuit of breakthrough scientific discoveries that successfully enhance preclinical and clinical research.
B-lymphocyte antigen CD19, also known as CD19 molecule (cluster of differentiation 19), B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12 and CVID3, is a 95 kDa type I transmembrane glycoprotein belonging to the immunoglobulin (Ig) superfamily (IgSF), with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. The CD19 protein is encoded by the CD19 gene located on the short arm of 16p11.2 on chromosome 16. The gene consists of 15 exons, 4 encoding extracellular domains and 9 encoding cytoplasmic domains. The CD19 molecule contains 240 amino acid residues. The signal peptide is composed of the first 19 amino acids. It has two C2-type Ig-like extracellular domains composed of 20–294 amino acids. The first Ig-like ring is crucial for the correct 3D folding of CD19 and its final transport to the plasma membrane.
Fig.1 Structure of CD19
CD19 is a key component in the B cell receptor (BCR) signaling pathway. B cells express CD19 along with other proteins, including the BCR, on their surface. When an antigen binds to the BCR, it triggers a cascade of signals that activate the B cell and lead to the production of antibodies. In mature B cells, CD19 serves as a co-receptor in this process and helps to amplify the signal from the BCR. When the BCR binds to an antigen, CD19 is brought into close proximity with other signaling molecules and facilitates the activation of these molecules. This results in the activation of multiple downstream signaling pathways that eventually lead to the activation of the B cell and the production of antibodies. In this way, CD19 plays an important role in the immune response by helping to ensure that the B cell response is appropriately activated in response to antigens.
In developing B cells, however, CD19 may play a different role in regulating BCR signaling. In some cases, the differential regulation of BCR signaling by CD19 can become dysregulated in B-cell lymphoid malignancies, leading to the development of cancer. For example, in some cases of acute lymphoblastic leukemia (ALL), the cancer cells have a high affinity for BCR, leading to constitutive activation of BCR signaling and uncontrolled growth. In these cases, targeting CD19 can help disrupt the BCR signaling pathway and slow or halt the growth of the cancer cells. One approach is to use chimeric antigen receptor T cell (CAR-T) therapy, which involves genetically modifying a patient's own T cells to express a receptor that recognizes and binds to CD19. These modified T cells are then infused back into the patient, where they can specifically target and kill the cancer cells that express CD19.
Clinical trials of CD19-targeted CAR cell therapy have shown promising results, with response rates ranging from 50 to 90% in patients with relapsed or refractory B cell malignancies. The approval of CD19-targeted CAR-T cell therapies has revolutionized the treatment landscape for B cell malignancies, providing new hope for patients with these diseases who have exhausted conventional treatment options. As far, four CD19-targeted CAR-T cell products have been approved by the FDA for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). These products are made from autologous cells derived from the patient by leukapheresis and contain a CAR targeting CD19. The CAR transgene is transduced into cells using a replication-incompetent retrovirus (axicabtagene and brexucabtagene) or lentivirus (all others) and contains a costimulatory molecule (CD28 for axicabtagene and brexucabtagene; CD137, also known as 4-1BB, for all others).
Table 1. Approved CD19-Targeted CAR Cell Therapies
| Brand Name | Generic Name | Manufacturer | Indication | Date of FDA Approval |
| Kymriah | Tisagenlecleucel | Novartis | Pediatric and young adult (age≤25) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) | August 30, 2017 |
| Adult R/R diffuse large B-cell lymphoma (DLBCL) | May 1, 2018 | |||
| Yescarta | Axicabtagene ciloleucel | Kite Pharma | R/R DLBCL, primary mediastinal B-cell lymphoma (PMBCL), high- grade B-cell lymphoma, transformed follicular lymphoma (FL) | October 18, 2017 |
| R/R FL | March 5, 2021 | |||
| Tecartus | Brexucabtagene autoleucel | Kite Pharma | Mantle cell lymphoma | July 24, 2020 |
| Adult R/R B-cell ALL | October 1, 2021 | |||
| Breyanzi | Lisocabtagene maraleuecel | Juno Therapeutics | R/R large B-cell lymphoma | February 5, 2021 |
As far, ongoing CD19-targeted CAR therapy clinical trials are mainly focused on non-Hodgkin lymphoma (NHL), diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). Some of the key areas of focus in these trials include combination therapy, off-the-shelf CAR-T cells, next-generation CAR designs, and maintenance therapy. Over half of these ongoing clinical trials are in Phase I, and only a few have made it to Phase III or Phase II/III status. Among these CD19-targeted CAR cell therapy trials, a few are designed to target two targets, CD19 and B cell maturation antigen (BCMA), and focus on CD19/BCMA-expressing autoimmune diseases, such as immune nephritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, POEMS syndrome, and amyloidosis.
Table 2. Ongoing CD19 -Targeted CAR Cell Therapy Clinical Trials
| NCT Number | Title | Conditions | Sponsor/Collaborators | Phases |
| NCT05673447 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | Diffuse Large B Cell Lymphoma | Changhai Hospital|Nanjing Enricnk Biotech Co., Ltd | Early Phase 1 |
| NCT05453669 | Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL | B-cell Non-Hodgkin's Lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University|Zhejiang Ruijiamei Biotechnologies, Co., Ltd. | Phase 1 |
| NCT04661020 | CD19 CAR-T Therapy for Elderly Patients With B-cell Non-Hodgkin's Lymphoma | Non-hodgkin Lymphoma,B Cell | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT04532281 | A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies | Acute Lymphoblastic Leukemia|Non-Hodgkin Lymphoma of Soft Tissue | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT04532268 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | Acute Lymphoblastic Leukemia|Non-hodgkin Lymphoma,B Cell | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT05715606 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | Diffuse Large B-cell Lymphoma | Anhui Provincial Hospital|Leman Biotech Co., Ltd | Early Phase 1 |
| NCT05210907 | Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Seoul National University Hospital | Phase 1 |
| NCT05470777 | CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL | B-cell Acute Lymphoblastic Leukemia | The First Affiliated Hospital of Soochow University|National Natural Science Foundation of China(Grant No. 81970138)|Jiangsu Province Natural Science Foundation of China (Grant No. BK20210091)|Jining Medical University|The Second People's Hospital of Huai'an|First Affiliated Hospital Bengbu Medical College|Northern Jiangsu Province People's Hospital|Affiliated Hospital of Nantong University|Suzhou Hospital of Traditional Chinese Medicine | Phase 1|Phase 2 |
| NCT04684472 | Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies | Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Leukemia | Liqun Zou|Sichuan University | Phase 1 |
| NCT04639739 | Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. | NHL | Xinqiao Hospital of Chongqing|Chongqing Precision Biotech Co., Ltd | Early Phase 1 |
| NCT05432635 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Transformed Non-Hodgkin Lymphoma | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT05164042 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Relapse Leukemia|Refractory Leukemia | Shenzhen University General Hospital | Phase 1|Phase 2 |
| NCT03984968 | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Adult B-Cell | The First Affiliated Hospital of Soochow University | Phase 1|Phase 2 |
| NCT04289220 | Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia | B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia | Yan'an Affiliated Hospital of Kunming Medical University | Phase 1 |
| NCT04443829 | Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma | Primary CNS Lymphoma | University College, London | Phase 1 |
| NCT03937544 | Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL | Relapsed B Acute Lymphoblastic Leukaemia|Refractory B Acute Lymphoblastic Leukaemia | National University of Malaysia|Gaia Science | Phase 2|Phase 3 |
| NCT05436223 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Non-Hodgkin's Lymphoma | Hrain Biotechnology Co., Ltd.|Shanghai Zhongshan Hospital | Phase 2 |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma | Bambino Gesù Hospital and Research Institute | Phase 1|Phase 2 |
| NCT03275493 | Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia|CD19 Positive|Relapse|Refractory | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University | Phase 1|Phase 2 |
| NCT05333302 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | B-cell Acute Lymphoblastic Leukemia|Lymphoblastic B-Cell Lymphoma | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | Phase 1 |
| NCT04484012 | Modified Immune Cells (CD19 CAR-T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 2 |
| NCT04271410 | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | Leukemia|Lymphoma, Large B-Cell, Diffuse|Leukemia, B-cell|Lymphoma, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell | Chongqing Precision Biotech Co., Ltd | Phase 1|Phase 2 |
| NCT04271800 | Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | Leukemia|Lymphoma|Leukemia, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell | Chongqing Precision Biotech Co., Ltd | Phase 1|Phase 2 |
| NCT04653493 | CD19 Targeted CAR-T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)|Refractory B Cell Acute Lymphoblastic Leukemia (ALL) | Sabz Biomedicals|Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran|Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran | Phase 1 |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T) for Relapsed or Refractory B-cell Lymphoma | Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Large B-cell Lymphoma|Follicular Lymphoma Grade 3A|Follicular Lymphoma Grade 3B | Pell Bio-Med Technology Co., Ltd. | Phase 1|Phase 2 |
| NCT04100187 | Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia | Leukemia | Kecellitics Biotech Company Ltd|Hebei Yanda Ludaopei Hospital | Phase 1 |
| NCT04381741 | CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma | Diffuse Large B-cell Lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| NCT05707273 | CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission | B Acute Lymphoblastic Leukemia | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT02546739 | Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL | Leukemia|Lymphoma | Beijing Doing Biomedical Co., Ltd.|The First Hospital of Jilin University|Hebei Yanda Ludaopei Hospital | Phase 1 |
| NCT05176275 | PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells | Lymphoma | The First Affiliated Hospital of Soochow University | Not Applicable |
| NCT03774654 | CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | Refractory B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Small Lymphocytic Lymphoma|Relapsed Adult ALL|Relapsed CLL|Relapsed Non Hodgkin Lymphoma | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute | Phase 1 |
| NCT03373071 | Anti-CD19 CAR-T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL | CD19-ALL|CD19-LNH | Bambino Gesù Hospital and Research Institute | Phase 1|Phase 2 |
| NCT05143112 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma | Non-hodgkin Lymphoma,B Cell | Shenzhen University General Hospital | Phase 1|Phase 2 |
| NCT05625594 | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma | Central Nervous System Lymphoma | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT05679687 | ThisCART19A Bridging to alloHSCT for R/R B-ALL | CAR|Refractory Acute Lymphoblastic Leukemia|Relapsed Adult ALL | The First Affiliated Hospital of Soochow University|Fundamenta Therapeutics, Ltd. | Phase 1 |
| NCT04795882 | A New Study Evaluating the Activity of Modular CAR-T for mYeloma | Multiple Myeloma | University College, London | Phase 1 |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma | B-cell Acute Lymphoblastic Leukemia|B-Cell Lymphoma, Unspecified | Zhujiang Hospital|Guangdong Zhaotai Cell Bio-tech Co., LTD | Phase 1|Phase 2 |
| NCT05645601 | CAR-NK Targeted CD19 for r/r B-cell Malignancies | Adult Relapsed/Refractory B-cell Hematologic Malignancies | Affiliated Hospital to Academy of Military Medical Sciences|Beijing JD Biotech Co. LTD. | Phase 1 |
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | B Cell Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine | Phase 1 |
| NCT05659628 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | Diffuse Large B-cell Lymphoma | Ningbo No. 1 Hospital|Zhejiang University | Phase 1 |
| NCT04796675 | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non Hodgkin's Lymphoma | Wuhan Union Hospital, China|Shanghai Simnova Biotechnology Co.,Ltd. | Phase 1 |
| NCT05410041 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non Hodgkin Lymphoma | Beijing Boren Hospital | Phase 1 |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Burkitt Lymphoma | Wuhan Union Hospital, China|Wuhan Si'an Medical Technology Co., Ltd | Phase 3 |
| NCT05665062 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | CLL/SLL|NHL|Mantle Cell Lymphoma|Follicular Lymphoma|Large B-cell Lymphoma|Indolent B-Cell Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma | Synthekine | Phase 1 |
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | Adult Grade III Lymphomatoid Granulomatosis|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrm Macroglobulinemia | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT05554939 | Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL | Non Hodgkin's Lymphoma | Chinese PLA General Hospital | Phase 1|Phase 2 |
| NCT05269914 | Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL | Diffuse Large B Cell Lymphoma | The Affiliated Hospital of Qingdao University | Not Applicable |
| NCT04637763 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkin|Relapsed Non Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Non Hodgkin Lymphoma|Lymphoma|B Cell Lymphoma|B Cell Non-Hodgkin's Lymphoma | Caribou Biosciences, Inc. | Phase 1 |
| NCT03720457 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | CD19-positive|Diffuse Large B-cell Lymphoma|Follicular Lymphoma | Hrain Biotechnology Co., Ltd.|Shanghai Zhongshan Hospital | Phase 1 |
| NCT05472558 | Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | B-cell Non Hodgkin Lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| NCT01087294 | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | Phase 1 |
| NCT03064269 | CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | B-cell Acute Lymphocytic Leukemia | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University | Phase 1 |
| NCT05239676 | Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma | Lymphoma | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT04881240 | Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory|Pediatric ALL | St. Jude Children's Research Hospital | Phase 1 |
| NCT04887012 | Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | B-cell Non Hodgkin Lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| NCT01683279 | A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia | B Cell Leukemia | Seattle Children's Hospital | Phase 1 |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies | NHL, Relapsed, Adult|B-cell Lymphoma|B-cell Leukemia|DLBCL - Diffuse Large B Cell Lymphoma|ALL, Adult B Cell|ALL, Childhood|CLL/SLL | Athenex, Inc. | Phase 1 |
| NCT05381662 | CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment | Acute Lymphoblastic Leukemia in Remission | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University | Phase 1|Phase 2 |
| NCT05585996 | Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma | Relapsed and Refractory B-cell Lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| NCT04943016 | CD19 CAR-T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies | Relapsed/Refractory B-Cell Malignancies | National Taiwan University Hospital | Phase 1 |
| NCT02050347 | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) | Non-Hodgkin's Lymphoma|B-Cell ALL|B-Cell CLL | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute | Phase 1 |
| NCT04649112 | Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies | CD19 Expressing Malignancies|Hematologic Malignancy | Precision BioSciences, Inc. | Phase 1 |
| NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | B-cell Acute Lymphoblastic Leukemia|B Lineage Lymphoblastic Lymphoma | Stephan Grupp MD PhD|University of Pennsylvania|Children's Hospital of Philadelphia | Phase 1|Phase 2 |
| NCT02028455 | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia | CD19+ Acute Leukemia | Seattle Children's Hospital | Phase 1|Phase 2 |
| NCT04325841 | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children | Acute Lymphoblastic Leukemia, Pediatric|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia | Beijing Boren Hospital | Phase 2 |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | Acute Lymphoblastic Leukemia, Adult|Acute Lymphoblastic Leukemia, Pediatric|Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma | University Hospital Heidelberg | Phase 1|Phase 2 |
| NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute | Phase 1 |
| NCT05648019 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | Lymphoblastic Leukemia|Lymphoblastic Leukemia in Children|Lymphoblastic Leukemia, Acute Adult|B-cell Acute Lymphoblastic Leukemia|Large B-cell Lymphoma|CAR | KK Women's and Children's Hospital|Singapore General Hospital | Phase 2 |
| NCT04732845 | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies | Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia | Benjamin Tomlinson|Case Comprehensive Cancer Center | Phase 1 |
| NCT05385263 | Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion | B Cell Lymphoma | Tel-Aviv Sourasky Medical Center | Phase 2 |
| NCT04544592 | UCD19 CAR-T in Treatment of Pediatric B-ALL and B-NHL | B-cell Acute Lymphoblastic Leukemia|B-cell Non Hodgkin Lymphoma | University of Colorado, Denver|National Cancer Institute (NCI) | Phase 1|Phase 2 |
| NCT02146924 | Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT05574114 | A Study of Radiation Therapy Before CAR-T Cell Therapy for People With B Cell Lymphoma | Non-Hodgkin Lymphoma|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory | Memorial Sloan Kettering Cancer Center | Phase 1 |
| NCT02935257 | Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 | Leukemia, Lymphoblastic, Acute, Lymphoma | University College, London | Phase 1 |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies | Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia | Ottawa Hospital Research Institute | Phase 1|Phase 2 |
| NCT02051257 | Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT05052528 | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma | Mehrdad Abedi, MD|National Cancer Institute (NCI)|University of California, Davis | Phase 1 |
| NCT03666000 | Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL | Non-Hodgkin Lymphoma|B-cell Acute Lymphoblastic Leukemia | Precision BioSciences, Inc. | Phase 1|Phase 2 |
| NCT00840853 | Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT | Acute Lymphoblastic Leukemia (ALL)|Chronic Lymphocytic Leukemia (CLL)|Non Hodgkin's Lymphoma | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine | Phase 1 |
| NCT05665725 | Siltuximab for the Prevention of CAR-T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Timothy Voorhees|Ohio State University Comprehensive Cancer Center | Phase 1 |
| NCT03696784 | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Lymphoma|Lymphoma, B-Cell|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases | UNC Lineberger Comprehensive Cancer Center|Bellicum Pharmaceuticals|The V Foundation | Phase 1 |
| NCT05702853 | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | B-cell Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia | Medical University of South Carolina | Phase 1|Phase 2 |
| NCT05081479 | A Study of N-Acetylcysteine (N-AC)in People Receiving CAR T-cell Therapy for Lymphoma | Lymphoma | Memorial Sloan Kettering Cancer Center | Phase 1 |
| NCT04850560 | Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma | Objective Response Rate | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| NCT04792593 | Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | B-ALL | Hebei Senlang Biotechnology Inc., Ltd. | Not Applicable |
| NCT04796441 | Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation | AML | Hebei Senlang Biotechnology Inc., Ltd. | Not Applicable |
| NCT04257578 | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma | University of Washington|AstraZeneca | Phase 1|Phase 2 |
| NCT05440409 | CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL | Leukemia, Acute Lymphoblastic|Lymphoblastic Leukemia, Acute, Childhood | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | undefined |
| NCT00709033 | T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL | Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute | Phase 1 |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma|Grade 3b Follicular Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Transformed Follic Lymph to Diff Large B-Cell Lymphoma|Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma | Southwest Oncology Group|National Cancer Institute (NCI)|Genentech, Inc. | Phase 2 |
| NCT04640909 | Impact of Treatment With Targeted Therapies on the Generation of CAR-T Cells in CLL Patients | CLL|Chronic Lymphocytic Leukemia | Gruppo Italiano Malattie EMatologiche dell'Adulto | Not Applicable |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory B Acute Lymphoblastic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Fred Hutchinson Cancer Center|Juno Therapeutics, Inc. | Phase 1 |
| NCT05334823 | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | Acute Lymphoblastic Leukemia|Relapsed Pediatric ALL|Refractory Acute Lymphoblastic Leukemia | Chongqing Precision Biotech Co., Ltd | Phase 2 |
| NCT04888442 | Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| NCT05675982 | Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells | Diffuse Large B Cell Lymphoma | Centre Henri Becquerel | Not Applicable |
| NCT04049513 | ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) | Lymphomas Non-Hodgkin's B-Cell|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL) | Malaghan Institute of Medical Research|Wellington Zhaotai Therapies Limited (WZTL) | Phase 1 |
| NCT05260957 | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | Refractory Non-Hodgkin Lymphoma|Relapsed Non Hodgkin Lymphoma|Aggressive Non-Hodgkin Lymphoma | Lazaros Lekakis|Genentech, Inc.|University of Miami | Phase 2 |
| NCT03798509 | Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia | CD19-positive|Acute Lymphoblastic Leukemia | Hrain Biotechnology Co., Ltd.|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| NCT04608487 | Axi-cel in CNS Lymphoma | Lymphoma|Lymphoma Cns | Dana-Farber Cancer Institute|Kite, A Gilead Company | Phase 1 |
| NCT04690192 | CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma | Large B-cell Lymphoma | Zou Dehui|Juventas Cell Therapy Ltd.|Institute of Hematology & Blood Diseases Hospital | Phase 1|Phase 2 |
| NCT04545762 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma|Burkitt Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Diffuse Large B Cell Lymphoma|Small Lymphocytic Lymphoma|Transformed Lymphoma | C. Babis Andreadis|University of California, Davis|University of California, San Francisco | Phase 1 |
| NCT04892277 | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia | Mayo Clinic | Phase 1 |
| NCT03155191 | Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Takara Bio Inc. | Phase 1|Phase 2 |
| NCT05691153 | ThisCART19A for B-NHL Relapsed After Auto-CAR T | CAR|B Cell Lymphoma|Relapsed Non-Hodgkin Lymphoma | The First Affiliated Hospital of Soochow University|Fundamenta Therapeutics, Ltd. | Phase 1 |
| NCT03618381 | EGFR806 CAR-T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma | Seattle Children's Hospital | Phase 1 |
| NCT03853616 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Acute Lymphoblastic Leukemia Recurrent|B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory|Chronic Lymphocytic Leukemia Recurrent|Chronic Lymphocytic Leukemia Refractory | Miltenyi Biomedicine GmbH | Phase 1|Phase 2 |
| NCT04880434 | Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | Relapsed/Refractory Mantle Cell Lymphoma | Kite, A Gilead Company|Gilead Sciences | Phase 2 |
| NCT03455972 | Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT | Safety and Efficacy | The First Affiliated Hospital of Soochow University | Phase 1|Phase 2 |
| NCT02601313 | Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory Mantle Cell Lymphoma | Kite, A Gilead Company|Gilead Sciences | Phase 2 |
| NCT03186118 | Pilot Study of T-APCs Following CAR-T Cell Immunotherapy for CD19+ Leukemia | CD 19+ Acute Leukemia | Seattle Children's Hospital | Phase 1 |
| NCT04303247 | CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL | B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent | Xinqiao Hospital of Chongqing|Gracell Biotechnology Shanghai Co., Ltd.|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|The Affiliated Hospital Of Guizhou Medical University|Tang-Du Hospital|The General Hospital of Western Theater Command|Chongqing University Cancer Hospital | Early Phase 1 |
| NCT01318317 | Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1|Phase 2 |
| NCT04638270 | Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL | Lymphoma, Non-Hodgkin | Xinqiao Hospital of Chongqing|Gracell Biotechnology Shanghai Co., Ltd.|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|The Second Affiliated Hospital of Chongqing Medical University|The Affiliated Hospital Of Guizhou Medical University|The Second Affiliated Hospital of Kunming Medical University|Chongqing University Cancer Hospital | Early Phase 1 |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|High Grade B-Cell Lymphoma, Not Otherwise Specified|Post-Transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hairy Cell Leukemia|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT05618041 | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | Acute Lymphoblastic Leukemia|Lymphoma|Multiple Myeloma | Hebei Senlang Biotechnology Inc., Ltd. | Not Applicable |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | Acute Myeloid Leukemia | Sheba Medical Center | Phase 2|Phase 3 |
| NCT03407859 | Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL | Therapy Related Leukemia | Zhujiang Hospital|Nanfang Hospital of Southern Medical University | Early Phase 1 |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | B-cell Acute Lymphoblastic Leukemia | Hrain Biotechnology Co., Ltd.|Second Affiliated Hospital of Nanchang University | Early Phase 1 |
| NCT04287309 | CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS | Hematological Malignancy | Zhejiang University | undefined |
| NCT05370547 | Chidamide Bridging for CAR-T Therapy | Non Hodgkin's Lymphoma | Chinese PLA General Hospital | Phase 1|Phase 2 |
| NCT05664217 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Non-Hodgkin Lymphoma|Relapsed/Refractory Diffuse Large B-cell Lymphoma | Nektar Therapeutics | Phase 2|Phase 3 |
| NCT04637269 | Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma | Multiple Myeloma | Xinqiao Hospital of Chongqing|Carbiogene Therapeutics Co. Ltd. | Early Phase 1 |
| NCT02614066 | A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Kite, A Gilead Company|Gilead Sciences | Phase 1|Phase 2 |
| NCT05098613 | Preliminary Safety and Tolerability of CD19x22 CAR-T Cells in Adolescent and Adult R/R B-NHL Patients | Non-Hodgkin Lymphoma | University of Colorado, Denver | Phase 1 |
| NCT05535673 | Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma | Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL | Zhengzhou University|Fundamenta Therapeutics, Ltd. | Phase 1 |
| NCT04703686 | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | Diffuse Large B-Cell Lymphoma Refractory|Refractory Indolent Adult Non-Hodgkin Lymphoma|Refractory Transformed B-cell Non-Hodgkin Lymphoma|Refractory Primary Mediastinal Large B-Cell Cell Lymphoma|Refractory Mantle Cell Lymphoma | The Lymphoma Academic Research Organisation | Phase 2 |
| NCT05085418 | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis | Immune Nephritis|Autoimmune Diseases|Lupus Nephritis | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT05085444 | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma | Scleroderma|Autoimmune Diseases | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT05085431 | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome | Sjogren's Syndrome|Autoimmune Diseases | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT05030779 | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus|Autoimmune Diseases | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT05640713 | Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy | Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited | Henan Cancer Hospital|Fundamenta Therapeutics, Ltd. | Phase 1 |
| NCT05106907 | Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma | B-cell Malignancy | Fundamenta Therapeutics, Ltd.|The Affiliated Hospital of Xuzhou Medical University | Phase 1 |
| NCT03761056 | Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma | B-cell Lymphoma | Kite, A Gilead Company|Gilead Sciences | Phase 2 |
| NCT04384393 | Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies | B Cell Malignancy | Fundamenta Therapeutics, Ltd.|Anhui Provincial Hospital | Phase 1 |
| NCT05667155 | Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | B-cell Non Hodgkin Lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| NCT02349698 | A Clinical Research of CAR-T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | Leukemia|Lymphoma | Southwest Hospital, China | Phase 1|Phase 2 |
| NCT05576181 | Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia | Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited | Fundamenta Therapeutics, Ltd.|The First Affiliated Hospital of Zhengzhou University | Phase 1 |
| NCT05651100 | Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | Lymphoma, B-Cell | Kecellitics Biotech Company Ltd|Hebei Yanda Ludaopei Hospital | Phase 1|Phase 2 |
| NCT04162353 | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | Multiple Myeloma in Relapse|Refractory Multiple Myeloma|Plasmacytoid; Lymphoma | iCell Gene Therapeutics|iCAR Bio Therapeutics Ltd.|Peking University Shenzhen Hospital | Phase 1 |
| NCT04788472 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL | B-Cell Acute Lymphoblastic Leukemia, Adult | Zhejiang University|Yake Biotechnology Ltd. | Phase 1|Phase 2 |
| NCT04740203 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | B-Cell Acute Lymphoblastic Leukemia, Adult | Zhejiang University|Yake Biotechnology Ltd. | Phase 1|Phase 2 |
| NCT04626739 | CAR-T Cells in Treating Patients With Relapsed or Refractory NHL | Refractory Indolent Adult Non-Hodgkin Lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Early Phase 1 |
| NCT04531046 | Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation | B-Cell Lymphoma Refractory|B-cell Lymphoma Recurrent | The Lymphoma Academic Research Organisation | Phase 2 |
| NCT04626765 | CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia | Childhood Acute Lymphoblastic Leukemia | Hebei Senlang Biotechnology Inc., Ltd.|The Second Hospital of Hebei Medical University | Early Phase 1 |
| NCT04626726 | Adult B-ALL Treated by CAR-T Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | Adult B Acute Lymphoblastic Leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Early Phase 1 |
| NCT05400109 | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | Non Hodgkin Lymphoma | James Michael Martin|Case Comprehensive Cancer Center | Phase 1 |
| NCT02625480 | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia|Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Kite, A Gilead Company|Gilead Sciences | Phase 1|Phase 2 |
| NCT04340154 | Study of Sequential CAR-T Cell Treating Leukemia Children | Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoid Leukemia | Beijing Boren Hospital | Phase 2 |
| NCT05166070 | An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | Solid Tumor | The First Affiliated Hospital with Nanjing Medical University|Shanghai IASO Biotechnology Co., Ltd | Early Phase 1 |
| NCT05141253 | Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | Cancer | Tongji Hospital|Shanghai IASO Biotechnology Co., Ltd | Early Phase 1 |
| NCT04836507 | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients | Relapsed Large B-cell Lymphoma|Refractory Large B-cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|High-grade B-cell Lymphoma|Transformed Follicular Lymphoma (TFL) | Curocell Inc. | Phase 1|Phase 2 |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Relapsed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma (TFL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|High Grade B-cell Lymphoma (HGBCL) | Kite, A Gilead Company|Gilead Sciences | Phase 1|Phase 2 |
| NCT05528887 | Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies | Relapsed/Refractory Hematological Malignancies|Lymphoma|Myeloma|Leukemia | The Affiliated People's Hospital of Ningbo University|UTC Therapeutics Inc. | Phase 1 |
| NCT05429905 | Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia | Lymphoblastic Leukemia|Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Leukemia in Children|Lymphoblastic Leukemia, Acute Adult|CAR | KK Women's and Children's Hospital|Singapore General Hospital|National University Hospital, Singapore | Phase 1|Phase 2 |
| NCT05020015 | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Takeda | Phase 2 |
| NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Kite, A Gilead Company|Gilead Sciences | Phase 3 |
| NCT05263817 | A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis | POEMS Syndrome|Amyloidosis|Autoimmune Hemolytic Anemia|Vasculitis | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Acute Myeloid Leukemia (AML)|B-cell Non-Hodgkin's Lymphoma (B-NHL)|Multiple Myeloma (MM)|T-Cell Leukemia/Lymphoma, Adult|B-cell Acute Lymphoblastic Leukemia (B-ALL) | Shanghai Pudong Hospital|UTC Therapeutics Inc. | Phase 1 |
| NCT03938987 | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) | Relapsed Non Hodgkin Lymphoma|Relapsed Adult ALL|Relapsed Pediatric ALL | University of Alberta|Alberta Cancer Foundation|Canadian Cancer Trials Group | Phase 1|Phase 2 |
| NCT05537766 | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies | Relapsed/Refractory Waldenstrom Macroglobulinemia|Relapsed/Refractory Richter Transformation|Relapsed/Refractory Burkitt Lymphoma|Relapsed/Refractory Hairy Cell Leukemia | Kite, A Gilead Company|Gilead Sciences | Phase 2 |
| NCT05359211 | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Grade 3b Follicular Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Grade 3b Follicular Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Fred Hutchinson Cancer Center|Nektar Therapeutics | Phase 1 |
| NCT04790747 | Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions | Hematological Malignancies | Zhejiang University|Yake Biotechnology Ltd. | Phase 1|Phase 2 |
| NCT02659943 | T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies | Lymphoma, B-Cell|Lymphoma, Non-hodgkins | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | Phase 1 |
| NCT04488354 | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T | Relapsed/Refractory B-cell Lymphomas|Diffuse Large B-Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Chronic Lymphocytic Leukemia (CLL)|Marginal Zone Lymphoma (MZL)|Mantle Cell Lymphoma (MCL)|Small Lymphocytic Lymphoma (SLL)|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Burkitt Lymphoma | Calibr, a division of Scripps Research | Phase 1 |
| NCT04700319 | CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies | CAR | PersonGen BioTherapeutics (Suzhou) Co., Ltd.|Anhui Provincial Hospital | Early Phase 1 |
| NCT05523661 | Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients | Ph Positive ALL|CAR-T Cell|Dasatinib | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| NCT04781634 | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL | B-ALL | Chongqing Precision Biotech Co., Ltd | Phase 1|Phase 2 |
| NCT04782193 | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | B Cell Lymphoma | Chongqing Precision Biotech Co., Ltd | Phase 1|Phase 2 |
| NCT02443831 | CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies | Acute Lymphoblastic Leukemia|Burkitt Lymphoma | University College, London | Phase 1 |
| NCT03330691 | A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia | Leukemia|Lymphoma | Seattle Children's Hospital | Phase 1 |
| NCT05507827 | Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) | Lymphoid Leukemia | Crystal Mackall, MD|Orca Biosystems, Inc.|Stanford University | Phase 1 |
| NCT03241940 | Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia | Crystal Mackall, MD|Stanford University | Phase 1 |
| NCT04648475 | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | Leukemia, B-cell|Lymphoma, B-Cell | Chongqing Precision Biotech Co., Ltd | Phase 1|Phase 2 |
| NCT05225831 | Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia | CD19+ and CD 22+ B-ALL | Hebei Senlang Biotechnology Inc., Ltd.|Hebei Yanda Ludaopei Hospital | Early Phase 1 |
| NCT03233854 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive | Crystal Mackall, MD|California Institute for Regenerative Medicine (CIRM)|Stanford University | Phase 1 |
| NCT05421663 | A Study of C-CAR039 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | B Cell Non-Hodgkin's Lymphoma | Cellular Biomedicine Group, Inc.|City of Hope Medical Center | Phase 1 |
| NCT04450069 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | Relapsed/Refractory B-cell Lymphomas|Diffuse Large B Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Chronic Lymphocytic Leukemia (CLL)|Marginal Zone Lymphoma (MZL)|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma (SLL)|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Burkitt Lymphoma | Calibr, a division of Scripps Research | Phase 1 |
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR-T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | CD19 Positive|CD22 Positive|Minimal Residual Disease|Progressive Disease|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Phase 1|Phase 2 |
| NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recurrent Acute Lymphoblastic Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent High Grade B-Cell Lymphoma|Recurrent Indolent Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory B-Cell Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory High Grade B-Cell Lymphoma|Refractory Indolent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia | Sumithira Vasu|Ohio State University Comprehensive Cancer Center | Phase 1 |
| NCT05270772 | CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL | CD19+ Relapse/Refractory B-ALL | Chinese PLA General Hospital | Phase 1 |
| NCT04214886 | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | B-Cell Acute Lymphoblastic Leukemia, Adult|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent | Loyola University|Leukemia Research Foundation | Phase 1 |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | Multiple Myeloma in Relapse|Multiple Myeloma, Refractory|Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphocytic Leukaemia Refractory|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory | Zhejiang University|Yake Biotechnology Ltd. | Early Phase 1 |
| NCT04714593 | Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia | Acute Lymphocytic Leukemia, B-Cell | Shanxi Province Cancer Hospital|Shanghai Ultra-T Immune Therapeutics Co. LTD | Phase 1|Phase 2 |
| NCT03919526 | Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL | MRD-positive|Acute Lymphoblastic Leukemia | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| NCT04877080 | CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL | B-cell Lymphoma | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | Shanxi Province Cancer Hospital|Shanghai Ultra-T Immune Therapeutics Co. LTD | Phase 1|Phase 2 |
| NCT04715217 | Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma | Lymphoma, B-Cell | Shanxi Province Cancer Hospital|Shanghai Ultra-T Immune Therapeutics Co. LTD | Phase 1|Phase 2 |
| NCT03879382 | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES | POMES Syndrome|Relapsed and Refractory POMES Syndrome | Hrain Biotechnology Co., Ltd.|Shanghai Changzheng Hospital | Phase 1 |
| NCT04499573 | Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL | B-ALL | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 1|Phase 2 |
| NCT04846439 | Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL | Platelet Transfusion Refractoriness|Acute Leukemia in Remission | The First Affiliated Hospital of Soochow University|The Second People's Hospital of Huai'an|The First Affiliated Hospital with Nanjing Medical University|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1|Phase 2 |
| NCT03684889 | CD19-specific CAR-T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma | Leukemia|Lymphoma | Seattle Children's Hospital | Phase 1 |
| NCT03919240 | CAR-T Cell Therapy Targeting to CD19 for R/R ALL | Acute Lymphoblastic Leukemia With Failed Remission | The First Affiliated Hospital of Soochow University|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1|Phase 2 |
| NCT03271515 | Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL | Leukemia|Lymphoma | Beijing Doing Biomedical Co., Ltd. | Phase 1 |
| NCT04215016 | Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma | Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive | Fujian Medical University | Phase 1 |
| NCT05149391 | A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma | B Cell Non-Hodgkin's Lymphoma | Peking University|Peking University Cancer Hospital & Institute | Phase 1 |
| NCT05535855 | UCD19 CAR-T Therapy in Adults With B-ALL and MRD Positivity in CR1 | Acute Lymphoid Leukemia|Acute Lymphoblastic Leukemia | University of Colorado, Denver | Phase 1 |
| NCT05442515 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|Lymphoma, Non-Hodgkin | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | Phase 1|Phase 2 |
| NCT03383952 | A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia | B Cell Leukemia|B Cell Lymphoma | Immune Cell, Inc.|Weifang People's Hospital | Phase 1 |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Institute of Hematology & Blood Diseases Hospital|Juventas Cell Therapy Ltd. | Early Phase 1 |
| NCT03016377 | Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | Acute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative Disorders | UNC Lineberger Comprehensive Cancer Center|Bellicum Pharmaceuticals | Phase 1|Phase 2 |
| NCT03448393 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|Lymphoma, Non-Hodgkin | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | Phase 1 |
| NCT04718883 | CD19-targeted CAR-T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma | Mantle Cell Lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| NCT05705570 | A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies | Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia Refractory|B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory|Chronic Lymphocytic Leukemia Recurrent|Chronic Lymphocytic Leukemia Refractory | Hospital Israelita Albert Einstein|Miltenyi Biotec, Inc. | Phase 1 |
| NCT04007029 | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | CD19 Positive|CD20 Positive|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma | Jonsson Comprehensive Cancer Center|Parker Institute for Cancer Immunotherapy | Phase 1 |
| NCT04626908 | Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma | Relapsed and Refractory|Lymphoid Hematological Malignancies | He Huang|Gracell Biotechnology Ltd.|Zhejiang University | Phase 1|Phase 2 |
| NCT05436509 | CD19/79b Bi-specific CAR-T Cell Therapy | B Cell Malignancies | Shenzhen Geno-Immune Medical Institute | Phase 1|Phase 2 |
| NCT05114837 | Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL | Lymphoma Leukemia | Masonic Cancer Center, University of Minnesota | Phase 1|Phase 2 |
| NCT04037566 | CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. | Leukemia Lymphocytic Acute (ALL) in Relapse|Leukemia Lymphocytic Acute (All) Refractory|Lymphoma, B-Cell|CD19 Positive | Xijing Hospital|Xi'An Yufan Biotechnology Co.,Ltd | Phase 1 |
| NCT03085173 | A Trial of "Armored" CAR-T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Chronic Lymphocytic Leukemia (CLL)|Relapsed|Refractory | Memorial Sloan Kettering Cancer Center|Juno Therapeutics, Inc. | Phase 1 |
| NCT04812691 | CD19-targeted CAR-T Cells (JWCAR029) for Primary Refractory Diffuse Large B Cell Lymphoma | Diffuse Large B Cell Lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 1 |
| NCT05432882 | CD19/22 Bi-specific CAR-T Cell Therapy | B Cell Malignancies | Shenzhen Geno-Immune Medical Institute | Phase 1|Phase 2 |
| NCT04089215 | CD19-targeted CAR-T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | Lymphoma, Non-Hodgkin|Diffuse Large B Cell Lymphoma|Follicular Lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| NCT05436496 | CD19/70 Bi-specific CAR-T Cell Therapy | B Cell Malignancies | Shenzhen Geno-Immune Medical Institute | Phase 1|Phase 2 |
| NCT05206071 | Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma | Non-hodgkin's Lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Not Applicable |
| NCT04745559 | Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy | Diffuse Large-Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|High-grade B-cell Lymphoma (HGBCL)|Follicular Lymphoma | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| NCT04796688 | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies | Acute Lymphoblastic Leukemia|Chronic Lymphoblastic Leukemia|B-cell Lymphoma | Wuhan Union Hospital, China|Chengdu USino Technology Biology Co., Ltd | Phase 1 |
| NCT04697940 | Decitabine-primed Tandem CD19/CD20 CAR-T Cells Treatment in r/r B-NHL | Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma|Decitabine-primed Tandem CD19/CD20 CAR-T Cells | Han weidong|Chinese PLA General Hospital | Phase 1|Phase 2 |
| NCT04404660 | A Study of CD19 Targeted CAR-T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Autolus Limited | Phase 1|Phase 2 |
| NCT05223686 | To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. | Acute Lymphoblastic Leukemia | Hrain Biotechnology Co., Ltd.|Ruijin Hospital | Phase 1 |
| NCT04204161 | A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma | Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood|Refractory B-cell Acute Lymphoblastic Leukemia, Childhood|Relapsed/Refractory B-cell Lymphoma, Childhood | Shenzhen BinDeBio Ltd.|Xiangya Hospital of Central South University | Phase 1 |
| NCT04512716 | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | B-ALL|DLBCL|B ALL|Dlbcl-Ci|DLBCL Unclassifiable|DLBCL, Nos Genetic Subtypes|DLBCL Activated B-Cell Type|DLBCL Germinal Center B-Cell Type|Diffuse Large B-cell Lymphoma|HGBL|HGBL, Nos | Memorial Sloan Kettering Cancer Center|Actinium Pharmaceuticals | Early Phase 1 |
| NCT03573700 | Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory | St. Jude Children's Research Hospital | Phase 1|Phase 2 |
| NCT04214392 | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT03287817 | CD19/22 CAR-T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma | Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|DLBCL | Autolus Limited | Phase 1|Phase 2 |
| NCT02893189 | CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation | CD19+ Malignancies: Relapse Post-allogeneic Transplant | University College, London | Phase 1 |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Non Hodgkin Lymphoma | AbClon | Phase 1|Phase 2 |
| NCT05105867 | CD19 Targeted UCAR-T for CD19+ Refractory/Relapsed B-ALL/NHL | B-Cell Leukemia|B Cell Lymphoma | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|Gracell Biotechnology Shanghai Co., Ltd. | Early Phase 1 |
| NCT05651178 | Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients | Central Nervous System Lymphoma | Hrain Biotechnology Co., Ltd.|Second Affiliated Hospital of Nanchang University | Early Phase 1 |
| NCT03105336 | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | Follicular Lymphoma|Marginal Zone Lymphoma|Indolent Non-Hodgkin Lymphoma | Kite, A Gilead Company|Gilead Sciences | Phase 2 |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Lymphoma, Non-Hodgkin|B-cell Acute Lymphoblastic Leukemia|Large B-cell Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma|Waldenstrom Macroglobulinemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Aggressive Lymphoma|Large-cell Lymphoma | Nkarta Inc. | Phase 1 |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | Ependymoma|Glioblastoma|Medulloblastoma|Recurrent Metastatic Malignant Neoplasm in the Leptomeninges | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT04429438 | Multi-CAR-T Cells Targeting B Cell Lymphomas | B Cell Lymphoma (BCL) | Shenzhen Geno-Immune Medical Institute|The Seventh Affiliated Hospital of Sun Yat-sen University|Shenzhen Children's Hospital | Phase 1|Phase 2 |
| NCT04231747 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Lymphoma Non-Hodgkin|Agressive Lymphoma|Diffuse-large B-cell Lymphoma (DLBCL) | Juno Therapeutics, a Subsidiary of Celgene | Phase 1 |
| NCT04430530 | 4SCAR-T Therapy Post CD19-targeted Immunotherapy | CD19 Negative B-cell Malignancies | Shenzhen Geno-Immune Medical Institute|ShiJiaZhuang Zhongxi Children Hospital|Shenzhen Children's Hospital|The Seventh Affiliated Hospital of Sun Yat-sen University | Phase 1|Phase 2 |
| NCT05420493 | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Non Hodgkin Lymphoma | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| NCT05091541 | A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Non-Hodgkin's Lymphoma | Nanjing IASO Biotherapeutics Co.,Ltd | Phase 1|Phase 2 |
| NCT05054257 | CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma Refractory|Non-Hodgkin's Lymphoma, Relapsed | Institute of Hematology and Blood Transfusion, Czech Republic | Phase 1 |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | B-cell Acute Lymphoblastic Leukemia|B-ALL | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1|Phase 2 |
| NCT05654038 | A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies | B-Cell Lymphoblastic Leukemia/Lymphoma | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1|Phase 2 |
| NCT01840566 | High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma | Memorial Sloan Kettering Cancer Center | Phase 1 |
| NCT04510051 | CAR-T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children | Malignant Brain Neoplasm|Recurrent Malignant Brain Neoplasm|Refractory Malignant Brain Neoplasm | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT04049383 | CAR-20/19-T Cells in Pediatric and Young Adult Patients With Relapsed/Refractory B Cell ALL | Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia With Failed Remission|Acute Lymphoblastic Leukemia Recurrent|Acute Lymphoblastic Leukemia Not Having Achieved Remission|Acute Lymphoblastic Leukemia, Pediatric|Acute Lymphoblastic Leukemia | Medical College of Wisconsin|Children's Hospital and Health System Foundation, Wisconsin | Phase 1 |
| NCT04483778 | B7H3 CAR-T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma|Melanoma | Seattle Children's Hospital | Phase 1 |
| NCT02735291 | Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia | Leukemia | Sinobioway Cell Therapy Co., Ltd.|The Second Hospital of Anhui Medical University | Not Applicable |
| NCT04416984 | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR-T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) | Relapsed/Refractory Large B Cell Lymphoma | Allogene Therapeutics | Phase 1|Phase 2 |
| NCT03939026 | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma | Relapsed/Refractory Large B Cell Lymphoma|Relapsed/Refractory Follicular Lymphoma | Allogene Therapeutics | Phase 1 |
| NCT04016129 | CAR-T Immunotherapy Targeting CD19- ALL | B-cell Leukemia | Shenzhen Geno-Immune Medical Institute | Phase 1|Phase 2 |
| NCT04359784 | Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy | B-Cell Non-Hodgkin Lymphoma | Fred Hutchinson Cancer Center|Swedish Orphan Biovitrum | Phase 2 |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | B Cell Lymphoma|B Cell Leukemia|Myeloma|Hepatocellular Carcinoma|Pancreatic Carcinoma|Adenocarcinoma of Esophagogastric Junction | Kang YU|CARsgen Therapeutics Co., Ltd.|First Affiliated Hospital of Wenzhou Medical University | Not Applicable |
| NCT05480449 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | B Cell Acute Lymphoblastic Leukemia (B-ALL)|B Lineage Lymphoblastic Lymphoma | Stephan Grupp MD PhD|Children's Hospital of Philadelphia | Phase 1|Phase 2 |
| NCT01430390 | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies | Acute Lymphocytic Leukemia|Lymphoma | Memorial Sloan Kettering Cancer Center | Phase 1 |
| NCT05388695 | To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors | 19 and 22+ B Cell Hematologic Tumors|19 and 20+ B Cell Hematologic Tumors | Hebei Senlang Biotechnology Inc., Ltd.|Tongji Hospital | Phase 1 |
| NCT04889716 | CAR-T Followed by Bispecific Antibodies | Large B-cell Lymphoma | Abramson Cancer Center of the University of Pennsylvania|Genentech, Inc. | Phase 2 |
| NCT04173988 | Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | ALL, Childhood B-Cell | Children's Hospital of Fudan University | Early Phase 1 |
| NCT04778579 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy | Acute Lymphoid Leukemia | Sara V. Latorre|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Instituto de Salud Carlos III | Phase 2 |
| NCT04148430 | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | B Cell ALL|B-Cell Lymphoma|B-cell Non Hodgkin Lymphoma | Memorial Sloan Kettering Cancer Center | Phase 2 |
| NCT05474885 | BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) | Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) | iCell Gene Therapeutics|iCAR Bio Therapeutics Ltd. China | Phase 1 |
| NCT03144583 | Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy | Leukemia|Lymphoma | Sara V. Latorre|Instituto de Salud Carlos III|Institut d'Investigacions Biomèdiques August Pi i Sunyer | Phase 1 |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | B-Cell Lymphoma|B Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Lymphoplasmacytic Lymphoma|Chronic Lymphocytic Leukemia|Transformed Lymphoma | John Lister|Lentigen Technology, Inc.|Miltenyi Biotec, Inc.|AHN (Allegheny Health Network) Cancer Institute|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 2 |
| NCT03056339 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | B-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma | M.D. Anderson Cancer Center | Phase 1|Phase 2 |
| NCT04557436 | TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) | B Acute Lymphoblastic Leukemia | Great Ormond Street Hospital for Children NHS Foundation Trust|University College, London | Phase 1 |
| NCT05472610 | Study of Efficacy of BZ019 in Large B-cell Lymphoma | Large B-cell Lymphoma | Shanghai Mengchao Cancer Hospital|Shanghai Cell Therapy Group Co.,Ltd | Phase 2 |
| NCT04236011 | BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | Multiple Myeloma | Shanghai Changzheng Hospital|Gracell Biotechnology Shanghai Co., Ltd. | Early Phase 1 |
| NCT05010564 | CAR-T Cell, B-cell Acute Lymphoblastic Leukemia (TriCAR) | Leukemia, B-Cell | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute | Phase 1 |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma|Chronic Lymphocytic Leukemia|Indolent Non-Hodgkin Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Burkitt's Lymphoma|Primary CNS Lymphoma | Memorial Sloan Kettering Cancer Center|Takeda | Phase 1 |
| NCT03614858 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | Leukemia, B-cell | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University | Phase 1|Phase 2 |
| NCT05391490 | Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies | Blood Cancer | University College, London | Phase 1 |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | Non Hodgkin Lymphoma (NHL)|Mantle Cell Lymphoma (MCL)|Chronic Lymphocytic Leukemia (CLL)|Follicular Lymphoma|Marginal Zone Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Medical College of Wisconsin | Phase 1|Phase 2 |
| NCT03873805 | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT05404048 | PD-L1 PET-imaging During CAR T-cell Therapy | Large B-cell Lymphoma | University Medical Center Groningen | Phase 2 |
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | B-cell Non Hodgkin Lymphoma|B-cell Chronic Lymphocytic Leukemia | Medical College of Wisconsin|Miltenyi Biomedicine GmbH | Phase 1 |
| NCT05627323 | CAR-T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Glioblastoma Multiforme of Brain | Chimeric Therapeutics | Phase 1 |
| NCT04213469 | PD1-CD19-CART in Patients With r/r B-cell Lymphoma | B-cell Lymphoma | Bioray Laboratories|First Affiliated Hospital of Zhejiang University | Not Applicable |
| NCT03902197 | CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients | Acute Lymphoblastic Leukemia | Xuanwu Hospital, Beijing|Beijing Children's Hospital | Phase 2 |
| NCT04440436 | Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | NHL | Beijing Immunochina Medical Science & Technology Co., Ltd.|Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1|Phase 2 |
| NCT05412329 | Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma | Multiple Myeloma | Shanghai Changzheng Hospital|Gracell Biotechnology Shanghai Co., Ltd. | Phase 1 |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1|Phase 2 |
| NCT04107285 | Looking at Brain Changes in People With Lymphoma Receiving CAR-T Therapy | Lymphoma Receiving CAR-T Therapy | Memorial Sloan Kettering Cancer Center | undefined |
| NCT03389035 | Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT | Acute Lymphoblastic Leukemia, in Relapse | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Phase 1|Phase 2 |
| NCT04792489 | DALY 2.0 USA/ MB-CART2019.1 for DLBCL | DLBCL | Miltenyi Biomedicine GmbH | Phase 2 |
| NCT05672173 | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation | Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Transformed Chronic Lymphocytic Leukemia|Richter Syndrome | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 2 |
| NCT03960840 | CD19-specific CAR-T Cells in CLL/SLL, DLBCL and ALL | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia | Novartis Pharmaceuticals|Novartis | Phase 1 |
| NCT03870945 | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) | B-cell Non Hodgkin Lymphoma | Miltenyi Biomedicine GmbH|ICON plc | Phase 1|Phase 2 |
| NCT03244306 | A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma | Leukemia | Seattle Children's Hospital | Phase 1 |
| NCT04226989 | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy | Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma | He Huang|Nanjing Bioheng Biotech Co., Ltd.|Zhejiang University | Early Phase 1 |
| NCT04989803 | Study Evaluating the Safety and Efficacy of KITE-363 in Participants With Relapsed and/or Refractory B-cell Lymphoma | Relapsed and/or Refractory B-cell Lymphoma | Kite, A Gilead Company|Gilead Sciences | Phase 1 |
| NCT04119024 | Gene Modified Immune Cells (IL13Ralpha2 CAR-T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8|IL13RA2 Positive|Metastatic Melanoma|Cutaneous Melanoma, Stage III|Cutaneous Melanoma, Stage IV | Jonsson Comprehensive Cancer Center|City of Hope National Medical Center | Phase 1 |
| NCT05641428 | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL | NHL|DLBCL - Diffuse Large B Cell Lymphoma | University Medical Center Groningen|Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| NCT04290000 | Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies | Lymphoma and Acute Lymphoblastic Leukemia | University Hospital, Montpellier | undefined |
| NCT05312801 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkin Lymphoma, B-Cell | Luminary Therapeutics|Case Comprehensive Cancer Center | Phase 1 |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | Recurrent Glioblastoma|Refractory Glioblastoma | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 |
| NCT05292898 | A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Institute of Hematology & Blood Diseases Hospital|Nanjing Legend Biotech Co. | Phase 1 |
| NCT05130489 | CAR-T Cell Therapy Related Cardiovascular Outcomes | Cardiovascular Diseases|B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Diffuse Large B Cell Lymphoma|Cardiotoxicity|Cardiovascular Complication | University College London Hospitals | undefined |
| NCT05381181 | Safety and Efficacy Evaluation of Next-generation CD19-UCART | Acute Lymphoblastic Leukemia|Non Hodgkin Lymphoma | Bioray Laboratories|The First Affiliated Hospital of Zhengzhou University | Phase 1 |
| NCT05631912 | TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL | Non-hodgkin Lymphoma,B Cell | Chinese PLA General Hospital | Phase 1|Phase 2 |
| NCT02208362 | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma | Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma|Refractory Glioblastoma|Refractory Malignant Glioma|Refractory WHO Grade II Glioma|Refractory WHO Grade III Glioma | City of Hope Medical Center|National Cancer Institute (NCI)|Food and Drug Administration (FDA) | Phase 1 |
| NCT04340167 | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children | Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia | Beijing Boren Hospital | Phase 2 |
| NCT02631044 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle-cell Lymphoma|Primary Mediastinal B-cell Lymphoma | Juno Therapeutics, a Subsidiary of Celgene | Phase 1 |
| NCT03383965 | CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas | Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma | Immune Cell, Inc.|Weifang People's Hospital | Phase 1 |
| NCT04684563 | huCART19-IL18 in NHL/CLL Patients | Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma | University of Pennsylvania | Phase 1 |
| NCT01860937 | T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | Relapsed B-Cell Acute Lymphoblastic Leukemia | Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital | Phase 1 |
| NCT04276870 | Orphan Indications for CD19 Redirected Autologous T Cells | Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL|Infants With Very High Risk KMT2A B-ALL|Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation | Stephan Grupp MD PhD|University of Pennsylvania|Children's Hospital of Philadelphia | Phase 2 |
| NCT04595162 | A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | B-cell Acute Lymphoblastic Leukemia | Peking University Third Hospital|Gracell Biotechnology Ltd. | Phase 1 |
| NCT05077527 | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | AIDS-Related Diffuse Large B-cell Lymphoma|AIDS-Related Non-Hodgkin Lymphoma|HIV Infection|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3b Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma | AIDS Malignancy Consortium|National Cancer Institute (NCI) | Phase 1 |
| NCT03620058 | CART22 Alone or in Combination With huCART19 for ALL | Chemotherapy Resistant Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia | University of Pennsylvania | Phase 1 |
| NCT03196414 | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma | Multiple Myeloma | The First Affiliated Hospital of Soochow University | Phase 1|Phase 2 |
| NCT04419909 | Retreatment With CTL019/CTL119 | Lymphoma, B-Cell | University of Pennsylvania | Phase 1 |
| NCT03792633 | Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL | Acute Lymphoid Leukemia | University of Pennsylvania|Children's Hospital of Philadelphia | Phase 2 |
| NCT04935580 | Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients | Multiple Myeloma | Shanghai Changzheng Hospital|Gracell Biotechnology Shanghai Co., Ltd. | Phase 1|Phase 2 |
| NCT00466531 | Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | Leukemia | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Phase 1|Phase 2 |
| NCT05514327 | A Study of Ultra-fraction Radiotherapy Bridging CAR-T in R/R DLBCL | Diffuse Large B Cell Lymphoma|CAR-T|Radiotherapy|Bridging Therapy | Peking Union Medical College Hospital | Not Applicable |
| NCT05667506 | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | B-cell Acute Lymphoblastic Leukemia | Juventas Cell Therapy Ltd. | Phase 1|Phase 2 |
| NCT05460533 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Lymphoma (B-ALL) | B-cell Acute Lymphoblastic Leukemia | Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals | Phase 2 |
| NCT04844866 | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | Diffuse Large B-cell Lymphoma | Miltenyi Biomedicine GmbH|ICON plc | Phase 2 |
| NCT03226704 | Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing | Leukemia|Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Non-Hodgkin's Lymphoma | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | undefined |
| NCT02735083 | A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19 | Advanced Lymphoid Leukemia | Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier | Phase 1 |
| NCT05318963 | Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma | B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory | Qiu Lugui|Nanjing Legend Biotech Co.|Institute of Hematology & Blood Diseases Hospital | Phase 1 |
| NCT04827745 | Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL | Mixed Phenotype Acute Leukemia (MPAL)|Measurable Residual Disease (MRD) | University of Maryland, Baltimore | Phase 2 |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | B-cell Lymphoma|Non-Hodgkin Lymphoma|B-cell Malignancy|Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Large B-cell Lymphoma | CRISPR Therapeutics AG|CRISPR Therapeutics | Phase 1|Phase 2 |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence | B Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse | Assistance Publique - Hôpitaux de de Paris | Phase 1|Phase 2 |
| NCT04014894 | ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma | Leukemia|Lymphoma | Wuhan Union Hospital, China|Eureka(Beijing) Biotechnology Co., Ltd. | Phase 1 |
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
